RE-BVS – Piemonte Repository

Sfoglia per AUTORE
MASI G
Collezione ASL Biella

Items : 6

Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study. in Targeted oncology / Target Oncol. 2024 May;19(3):359-370. doi: 10.1007/s11523-024-01060-1. Epub 2024 May 1.

2024
ASL Biella
AOU Città della Salute di Torino

Aldrighetti L; Ratti F; De Rosa A; Zanuso V; Niger M; Fornaro L; Rossari F; Satolli MA; Garattini SK; Brandi G; Brunetti O; Leone F; Diana A; Pirrone C; Toma I; Pretta A; Landriscina M; Lorenzo A; Gusmaroli E; Bergamo F; Balsano R; Winchler C; Salani F; Formica V; Schirripa M; Aprile G; Garajova I; Martinelli E; Rapposelli IG; et alii...

Prognostic and predictive role of FGFR2 and IDH1 targetable alterations in advanced biliary tract cancer (aBTC): Data from the Italian ANITA dataset in Annals of Oncology

2024
ASL Biella

Genovesi V; Rimini M; Pressiani T; Soldà C; Nichetti F; Salvatore L; Antonuzzo L; Silvestro L; Diana A; Leone F; Foti S; Balsano R; Piva VM; Pircher CC; Camera S; Masi G; Rimassa L; De Grandis MC; Gardini AC; Fornaro L;

Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice. in Cancers / Cancers (Basel). 2023 Jan 31;15(3):900. doi: 10.3390/cancers15030900.

2023
AO Cuneo
ASL Biella

Fanotto V; Salani F; Vivaldi C; Scartozzi M; Ribero D; Puzzoni M; Montagnani F; Leone F; Vasile E; Bencivenga M; De Manzoni G; Basile D; Fornaro L; Masi G; Aprile G;

Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO in Annals of Oncology

2023
ASL Biella

Conca V; Antoniotti C; Bergamo F; Pietrantonio F; Rossini D; Scartozzi M; Perissinotto E; Leone A; Pusceddu V; Borelli B; Cavanna L; Latiano T; Santini D; Masi G; Salvatore L; Frassineti G; Leone F; Tamberi S; Boni L; Cremolini C;

Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy. in Journal of chemotherapy (Florence, Italy) / J Chemother. 2022 Dec;34(8):543-549. doi: 10.1080/1120009X.2022.2036557. Epub 2022 Feb 14.

2022
ASL Biella
AO Ordine Mauriziano
AOU Città della Salute di Torino

Cucchetti A; Ratti F; Aldrighetti L; Cascinu S; Burgio V; Faloppi L; Sperti E; Pellino A; Scartozzi M; Satolli MA; Salani F; Fenocchio E; Vivaldi C; Aprile G; Frega G; Aglietta M; Masi G; Filippi R; Galizia E; Palloni A; Santini D; Lonardi S; Lai E; Montagnani F; Pella N; Silvestris N; Fornaro L; Brandi G; Leone F; et alii...

Lactate dehydrogenase (LDH) levels to predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Subgroup analysis of the randomized BEBYP study in Journal of Clinical Oncology

2016
ASL Biella

Marmorino F; Cremolini C; Loupakis F; Barbara C; Dargenio F; Miraglio E; Masi G; Salvatore L; Marcucci L; Antonuzzo L; Chiara S; Banzi C; Schirripa M; Amoroso D; Bonetti A; Martignetti A; Paris M; Boni L; Tomcikova D; Falcone A;